ANYGEN has developed proprietary peptide manufacturing technology and owns the Jangseong Plant 1 and Osong Plant 2 GMP production facilities. Based on the APsoluT (AGM-330) platform technology, the company has discovered new drug candidates for breast cancer, gastric cancer, colorectal cancer, and viruses, and has established a core pipeline.

Peptide new drug development Generic peptide API manufacturing Customized peptide CDMO

Public

Pharma, CDMO, R&D Service